Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron. Web editor Nicole Raleigh speaks with Rob Abbott ...